Home > Healthcare > Medical Devices > Diagnostic Devices > Cardiac Biomarkers Market

Cardiac Biomarkers Market Size

Report ID: GMI7121
Published Date: Oct 2023
Report Format: PDF

Download Free Sample

Cardiac Biomarkers Market Size

Cardiac Biomarkers Market size was valued at USD 9.4 billion in 2022 and is estimated to account for USD 31.2 billion by 2032. Cardiac biomarkers are substances or molecules that are measured in the blood to assess the health and function of the heart.

To get key market trends

Download Free Sample

These biomarkers serve as diagnostic tools to detect and evaluate various cardiac conditions, including heart attack, failure, and other such disorders. According to the World Health Organization, cardiovascular diseases (CVDs) are the primary cause of global mortality, responsible for an estimated 18 million deaths each year.

Cardiac Biomarkers Market Report Attributes
Report Attribute	Details
Base Year:	2022
Cardiac Biomarkers Market Size in 2022:	USD 9.4 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	12.8%
2032 Value Projection:	USD 31.2 Billion
Historical Data for:	2018 to 2022
No. of Pages:	118
Tables, Charts & Figures:	223
Segments covered:	Product, Application, End-use, and Region
Growth Drivers:	Increase in prevalence of cardiovascular diseases Rise in the elderly population is leading to a higher prevalence of heart-related conditions Elevating clinical research studies that aim to discover novel cardiac biomarkers Increase in point-of-care testing
Pitfalls & Challenges:	Stringent regulatory framework Presence and advancement in cardiac imaging technologies

Learn more about the key segments shaping this market

Download Free Sample

Increasing prevalence of CVDs is likely to increase the demand for cardiac markers. As the number of individuals affected by CVDs increases, there will be a greater need for diagnostic tools and biomarkers to identify, assess, and manage these conditions. As people become more informed about the risk factors for CVDs, including high blood pressure, high cholesterol, obesity, smoking, and physical inactivity, they are increasingly motivated to monitor their heart health.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The cardiac biomarkers industry was valued at USD 9.4 billion in 2022 and is estimated to account for USD 31.2 billion by 2032.

The troponins segment garnered USD 3 billion revenue size in the year 2022 as the product’s exceptional sensitivity and specificity for cardiac injury make it indispensable in the early detection of myocardial infarction, the monitoring of heart-related disorders, and risk assessment in cardiovascular healthcare.

U.S. market accounted for USD 1.4 billion in 2022 and is predicted to witness substantial growth through 2032, owing to the rising cases of heart diseases in the region.

Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, Bio-Rad Laboratories, Ortho Clinical Diagnostics, Randox Laboratories, Quidel Corporation, and Radiometer among others.